A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers

Matthew G. Fury, Andrew Zahalsky, Richard Wong, Ennapadam Venkatraman, Eric Lis, Lucy Hann, Timothy Aliff, William Gerald, Martin Fleisher, David G. Pfister

Research output: Contribution to journalArticle

62 Citations (Scopus)

Abstract

Background: SU5416 (semaxanib) is a synthetic small molecule inhibitor of the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2). This Phase II study was conducted to determine the safety and efficacy of SU5416 in patients with recurrent or metastatic head and neck cancers. Patients and methods: This was an open label, single arm, Phase 2 study for patients who had received no more than 2 cytotoxic regimens. Thirty-five patients received intravenous SU5416 (145 mg/m2) twice per week by intravenous catheter. Radiologic imaging for response assessment was planned at the conclusion of each 8 week cycle. Serum VEGF levels and power Doppler ultrasound tumor imaging were explored as potential surrogate markers for SU5416 activity. Results: Thirty-two patients had received prior radiotherapy, including 18 patients who received prior concurrent chemoradiotherapy. Twelve patients had received prior chemotherapy in the recurrent disease setting. Thirty-one patients were evaluable for response. There was one partial response and one minor response. The median number of 8-week cycles received was 1 (range 1-4). Median overall survival was 6.25 months. The most common ≥ grade 3 toxicity was headache (31%). There was one fatal carotid artery hemorrhage. Fatigue, nausea, and vomiting were common grade 1-2 adverse events. Power Doppler ultrasound demonstrated decreased tumor vascularity in 5 of 7 patients. Conclusions: Treatment with SU5416 in patients with head and neck cancers is feasible, but objective responses are rare. Studies evaluating more potent anti-angiogenic agents in this disease are of interest.

Original languageEnglish (US)
Pages (from-to)165-172
Number of pages8
JournalInvestigational New Drugs
Volume25
Issue number2
DOIs
StatePublished - Apr 2007
Externally publishedYes

Fingerprint

Head and Neck Neoplasms
Doppler Ultrasonography
Semaxinib
Vascular Endothelial Growth Factor Receptor-2
Chemoradiotherapy
Carotid Arteries
Protein-Tyrosine Kinases
Nausea
Vascular Endothelial Growth Factor A
Vomiting
Fatigue
Headache
Neoplasms
Radiotherapy
Catheters
Biomarkers
Hemorrhage
Safety
Drug Therapy
Survival

Keywords

  • Head and neck squamous cell cancer
  • Phase II
  • SU5416
  • VEGFR2

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology

Cite this

Fury, M. G., Zahalsky, A., Wong, R., Venkatraman, E., Lis, E., Hann, L., ... Pfister, D. G. (2007). A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. Investigational New Drugs, 25(2), 165-172. https://doi.org/10.1007/s10637-006-9011-x

A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. / Fury, Matthew G.; Zahalsky, Andrew; Wong, Richard; Venkatraman, Ennapadam; Lis, Eric; Hann, Lucy; Aliff, Timothy; Gerald, William; Fleisher, Martin; Pfister, David G.

In: Investigational New Drugs, Vol. 25, No. 2, 04.2007, p. 165-172.

Research output: Contribution to journalArticle

Fury, MG, Zahalsky, A, Wong, R, Venkatraman, E, Lis, E, Hann, L, Aliff, T, Gerald, W, Fleisher, M & Pfister, DG 2007, 'A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers', Investigational New Drugs, vol. 25, no. 2, pp. 165-172. https://doi.org/10.1007/s10637-006-9011-x
Fury, Matthew G. ; Zahalsky, Andrew ; Wong, Richard ; Venkatraman, Ennapadam ; Lis, Eric ; Hann, Lucy ; Aliff, Timothy ; Gerald, William ; Fleisher, Martin ; Pfister, David G. / A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers. In: Investigational New Drugs. 2007 ; Vol. 25, No. 2. pp. 165-172.
@article{ed9c3f8c8d16414b90b65f739469db0e,
title = "A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers",
abstract = "Background: SU5416 (semaxanib) is a synthetic small molecule inhibitor of the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2). This Phase II study was conducted to determine the safety and efficacy of SU5416 in patients with recurrent or metastatic head and neck cancers. Patients and methods: This was an open label, single arm, Phase 2 study for patients who had received no more than 2 cytotoxic regimens. Thirty-five patients received intravenous SU5416 (145 mg/m2) twice per week by intravenous catheter. Radiologic imaging for response assessment was planned at the conclusion of each 8 week cycle. Serum VEGF levels and power Doppler ultrasound tumor imaging were explored as potential surrogate markers for SU5416 activity. Results: Thirty-two patients had received prior radiotherapy, including 18 patients who received prior concurrent chemoradiotherapy. Twelve patients had received prior chemotherapy in the recurrent disease setting. Thirty-one patients were evaluable for response. There was one partial response and one minor response. The median number of 8-week cycles received was 1 (range 1-4). Median overall survival was 6.25 months. The most common ≥ grade 3 toxicity was headache (31{\%}). There was one fatal carotid artery hemorrhage. Fatigue, nausea, and vomiting were common grade 1-2 adverse events. Power Doppler ultrasound demonstrated decreased tumor vascularity in 5 of 7 patients. Conclusions: Treatment with SU5416 in patients with head and neck cancers is feasible, but objective responses are rare. Studies evaluating more potent anti-angiogenic agents in this disease are of interest.",
keywords = "Head and neck squamous cell cancer, Phase II, SU5416, VEGFR2",
author = "Fury, {Matthew G.} and Andrew Zahalsky and Richard Wong and Ennapadam Venkatraman and Eric Lis and Lucy Hann and Timothy Aliff and William Gerald and Martin Fleisher and Pfister, {David G.}",
year = "2007",
month = "4",
doi = "10.1007/s10637-006-9011-x",
language = "English (US)",
volume = "25",
pages = "165--172",
journal = "Investigational New Drugs",
issn = "0167-6997",
publisher = "Kluwer Academic Publishers",
number = "2",

}

TY - JOUR

T1 - A Phase II study of SU5416 in patients with advanced or recurrent head and neck cancers

AU - Fury, Matthew G.

AU - Zahalsky, Andrew

AU - Wong, Richard

AU - Venkatraman, Ennapadam

AU - Lis, Eric

AU - Hann, Lucy

AU - Aliff, Timothy

AU - Gerald, William

AU - Fleisher, Martin

AU - Pfister, David G.

PY - 2007/4

Y1 - 2007/4

N2 - Background: SU5416 (semaxanib) is a synthetic small molecule inhibitor of the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2). This Phase II study was conducted to determine the safety and efficacy of SU5416 in patients with recurrent or metastatic head and neck cancers. Patients and methods: This was an open label, single arm, Phase 2 study for patients who had received no more than 2 cytotoxic regimens. Thirty-five patients received intravenous SU5416 (145 mg/m2) twice per week by intravenous catheter. Radiologic imaging for response assessment was planned at the conclusion of each 8 week cycle. Serum VEGF levels and power Doppler ultrasound tumor imaging were explored as potential surrogate markers for SU5416 activity. Results: Thirty-two patients had received prior radiotherapy, including 18 patients who received prior concurrent chemoradiotherapy. Twelve patients had received prior chemotherapy in the recurrent disease setting. Thirty-one patients were evaluable for response. There was one partial response and one minor response. The median number of 8-week cycles received was 1 (range 1-4). Median overall survival was 6.25 months. The most common ≥ grade 3 toxicity was headache (31%). There was one fatal carotid artery hemorrhage. Fatigue, nausea, and vomiting were common grade 1-2 adverse events. Power Doppler ultrasound demonstrated decreased tumor vascularity in 5 of 7 patients. Conclusions: Treatment with SU5416 in patients with head and neck cancers is feasible, but objective responses are rare. Studies evaluating more potent anti-angiogenic agents in this disease are of interest.

AB - Background: SU5416 (semaxanib) is a synthetic small molecule inhibitor of the tyrosine kinase domain of vascular endothelial growth factor receptor 2 (VEGFR2). This Phase II study was conducted to determine the safety and efficacy of SU5416 in patients with recurrent or metastatic head and neck cancers. Patients and methods: This was an open label, single arm, Phase 2 study for patients who had received no more than 2 cytotoxic regimens. Thirty-five patients received intravenous SU5416 (145 mg/m2) twice per week by intravenous catheter. Radiologic imaging for response assessment was planned at the conclusion of each 8 week cycle. Serum VEGF levels and power Doppler ultrasound tumor imaging were explored as potential surrogate markers for SU5416 activity. Results: Thirty-two patients had received prior radiotherapy, including 18 patients who received prior concurrent chemoradiotherapy. Twelve patients had received prior chemotherapy in the recurrent disease setting. Thirty-one patients were evaluable for response. There was one partial response and one minor response. The median number of 8-week cycles received was 1 (range 1-4). Median overall survival was 6.25 months. The most common ≥ grade 3 toxicity was headache (31%). There was one fatal carotid artery hemorrhage. Fatigue, nausea, and vomiting were common grade 1-2 adverse events. Power Doppler ultrasound demonstrated decreased tumor vascularity in 5 of 7 patients. Conclusions: Treatment with SU5416 in patients with head and neck cancers is feasible, but objective responses are rare. Studies evaluating more potent anti-angiogenic agents in this disease are of interest.

KW - Head and neck squamous cell cancer

KW - Phase II

KW - SU5416

KW - VEGFR2

UR - http://www.scopus.com/inward/record.url?scp=33845874370&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845874370&partnerID=8YFLogxK

U2 - 10.1007/s10637-006-9011-x

DO - 10.1007/s10637-006-9011-x

M3 - Article

C2 - 16983506

AN - SCOPUS:33845874370

VL - 25

SP - 165

EP - 172

JO - Investigational New Drugs

JF - Investigational New Drugs

SN - 0167-6997

IS - 2

ER -